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Reviewing Existing Knowledge Prior to Conducting Animal
Studies
Andrew Knight
Animal Consultants International, London, UK

Summary — Highly polarised viewpoints about animal experimentation have often prevented agreement.
However, important common ground between advocates and opponents was demonstrated within a discussion forum hosted at www.research-methodology.org.uk in July–August 2008, by the independent charity, SABRE Research UK. Agreement existed that many animal studies have methodological flaws — such as
inappropriate sample sizes, lack of randomised treatments, and unblinded outcome assessments — that may
introduce bias and limit statistical validity. There was also agreement that systematic reviews of the human
utility of animal models yield the highest quality of evidence, as their reliance on methodical and impartial
methods to select significant numbers of animal studies for review, serves to minimise bias. Unfortunately,
disagreement remained that animal experimental licence applications should reference systematic reviews of
existing studies, before approval. The UK Medical Research Council requires that researchers planning human
clinical trials must reference such reviews of related previous work. Existing knowledge is thereby fully and
appropriately utilised, and redundant experimentation is avoided. However, objections were raised that a similar requirement would interfere with animal experimental licensing, because, to date, there have been very
few systematic reviews of animal studies. In fact, the relative dearth of such reviews is a matter of considerable concern, and may partially explain the very poor human success rates of drugs that appear safe and/or
efficacious in animal trials. Nevertheless, the disturbing number of human trials which have proceeded concurrently with, or prior to, animal studies, or have continued despite equivocal evidence of efficacy in animals,
clearly demonstrate that many researchers fail to conduct adequate prior reviews of existing evidence. Where
neither sufficient primary studies, nor systematic reviews of such studies, exist, for citation within a licence
application, researchers should be able to provide evidence of this shortcoming, and, concurrently, demonstrate that the available literature and evidence have been adequately reviewed. This should also enable them
to clearly demonstrate the need and scientific appropriateness of their proposed study, the validity of its
design, and — importantly — that the benefits are reasonably likely to exceed the animal welfare, bioethical
and financial costs. Invasive animal studies should never be permitted solely on the basis of less probable,
speculative or intangible human benefits, or the mere satisfaction of scientific curiosity.
Key words: animal experiment, animal study, licence application, systematic review, Three Rs.
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Introduction
The high level of polarisation in the debate surrounding animal experimentation has often prevented agreement, and confused onlookers. It
was therefore heartening to read the recent contribution to an online discussion forum by Simon
Festing, Director of the Research Defence Society (RDS). It is clear that, despite our differences, those of us who are often critical of animal
experiments and those who frequently support
them, do share some important common ground.
The forum was hosted in July–August 2008, at
http://www.research-methodology.org.uk, by the
independent charity, SABRE Research UK.

SABRE aims to represent the interests of patients
and research volunteers by calling for “rigorous
scientific methods to assess the medical value of
research involving animals”, and avoids links with
any political parties, animal lobby groups or the
pharmaceutical industry (http:// www.sabre.org.
uk). The discussion in question focused on the
refusal of the RDS, the National Centre for the
Replacement, Refinement and Reduction of
Animals in Research (NC3Rs), and the Association
of Medical Research Charities (AMRC), to sign a
SABRE petition, available at http://petitions.number10.gov.uk/methodology/, stating that:
“We the undersigned petition the Prime Minister to
improve methods to evaluate the validity and rele-
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vance of animal experiments by requiring that: (i)
animal researchers are trained in experimental
design and statistics; (ii) each licence application
includes references to systematic reviews of existing
relevant studies; (iii) approved applications are
made available to researchers and others with relevant interest; and (iv) only the highest quality
experimental designs of animal studies and laboratory practice are permitted.”
On the face of it, such objectives appear eminently
reasonable. It is well recognised that many animal
studies employ inappropriate sample sizes.
Excessive numbers may waste animal lives and
other resources, whilst insufficient numbers may
invalidate the experimental results obtained, leading to unnecessary repetition. The quality of the
protocols used also varies considerably.
Suggested requirement (ii), for references to
systematic reviews of existing relevant studies in
project licence applications, is similar to the UK
Medical Research Council (MRC) requirement
that aims to ensure that researchers who are
planning human clinical trials appropriately reference systematic reviews of related previous
work, before proceeding (1). In this way, forthcoming experiments make the best use of existing
knowledge, and redundant experimentation is
avoided. Suggested requirement (iii) is similarly
necessary, to guide concurrent or future research,
prevent unnecessary experimental duplication,
and permit the legitimate scrutiny of the merits of
research.
It was surprising and disappointing that the
RDS, AMRC and NC3Rs felt unable to add their
names to this petition. This appears to represent a
missed opportunity to help create a broad and
united front in support of such laudable and obviously necessary measures. The NC3Rs declined to
comment on their refusal to sign the petition.

The AMRC Response
In its comment, the AMRC stated that, “While the
petition highlights the very real issue of ensuring
that animal research is carried out to high standards, we feel its aims and desired outcomes are
unclear and that it may amount in the end to little
more than an awareness raising exercise.”
In fact, the aims and desired outcomes of the
petition were explicitly stated. In addition, it is
surprising that the AMRC could consider
increased awareness about best practice to be in
any way problematic. The first step in achieving
consistency of best practice within animal research
is clearly the education of researchers, funding
agencies, ethics committees and journal editors,
concerning the importance of compliance with best
practice principles. It is elementary that we should
make the most of any opportunity to do so.
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The RDS Response
The objections to this petition cited by the RDS
were even more interesting. During their investigations, out of 19 current titles in the SABRE list
of relevant publications, the RDS had apparently
managed to randomly select all three of my own
listed publications, within a sample size of four!
Whilst I appreciate the attention afforded to my
studies, the RDS then criticised the objectivity of
my publications on the grounds that they considered me to be a “well-known antivivisectionist”. No
further data or reasons were provided. Although
not relevant to the points raised within the SABRE
petition, they cited these objections in support of
their reasons for declining to sign the petition.
I am unsure what exactly the RDS meant by
calling me a “well-known antivivisectionist”. My
main claim to such ‘fame’, if it may be so termed,
was my involvement in establishing a very successful veterinary surgical training programme
that involved neutering homeless cats and dogs to
increase their chances of adoption, rather than
killing healthy animals, when I was a veterinary
student. Surely the RDS cannot disapprove of
that?
Since then, I have published a series of critical
assessments on the contributions of various animal models toward human biomedical advancement. To minimise bias, large numbers of
published animal studies were selected randomly,
or via other methodical and impartial means. For
example, in some cases, all the studies within certain toxicity database subsets have been examined, without any discrimination. The results have
been published following rigorous peer-review,
including in ATLA (2), and neither the RDS nor
any other party has published any contrary evidence.
These results clearly demonstrate that, while
links to human healthcare advancements do exist,
the utility of animal models for such purposes is
generally poor. Simply stated, animal experimentation is not usually an efficient means of advancing human healthcare. These results are, I believe,
highly repeatable, and not difficult to demonstrate, by anyone interested in critically assessing
the value of large numbers of randomly-selected,
published animal studies.

Common Ground
In commenting further, however, Simon Festing of
the RDS indicated some important consistencies
between the viewpoints of advocates of animal
experimentation, and of those who frequently
oppose animal experiments. We appear to agree,
for example, that many animal studies have
methodological flaws ― such as inappropriate sam-
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ple sizes, lack of randomised treatments, and lack
of blinded outcome assessments ― that may introduce bias into the interpretation of the results, and
limit the statistical validity of any conclusions
drawn. Such deficiencies also occur within humanbased studies, although far less frequently. We
appear to agree that systematic reviews represent
the top of the evidence hierarchy, because their
reliance on methodical and impartial methods for
selecting studies for review is intended to minimise selection bias, thereby maximising the reliability of any conclusions reached.
We also agree that links between animal studies
and human healthcare advancements do exist.
Given the millions of animal studies conducted to
date, this is hardly surprising. The question is,
how common are those links? Or, more importantly, how efficient are animal models of humans,
when used to test the toxicity or efficacy of putative pharmaceuticals, or the benefits and adverse
effects of other clinical interventions? Are the public health-related benefits worth the animal welfare, ethical and financial costs inherent within
animal experimentation? Is it reasonably possible
that alternative research strategies might have
proven more efficient, had the available funds
been redirected toward them instead?
Whilst some such questions are destined to
remain speculative, answers to others may be indicated by systematic reviews of the utility of animal
experiments. My recent, published review of 27
other systematic reviews of the human clinical and
toxicological utility of various animal experimental models, provides one example (2).
Fortunately, it also appears likely that we can
agree on three of the four SABRE petition objectives, namely, suggested requirements (i), (iii) and
(iv).

Systematically Reviewing Existing
Knowledge
As voiced by Simon Festing, the remaining contentious requirement appears to be that: “(ii) each
licence application includes references to systematic reviews of existing relevant studies.” He voiced
the concern that some project licences might not be
granted, should references to systematic reviews
become required, because, to date, there have been
very few systematic reviews of animal studies.
Indeed, it is true that few such studies exist
within the field of animal-based research. The
dearth of such systematic reviews is, in fact, a
matter of grave concern, and may partially explain
the very poor human success rates of drugs that
appear to be safe and/or efficacious in animal trials. In fact, only 8% of all drugs progressing to
human trials after demonstration of safety in animal studies gain US Food and Drug Admin-

711

istration licensing approval (3). For example,
despite the existence of literature on the efficacy of
more than 700 drugs in treating experimental
models of stroke (4), only recombinant tissue plasminogen activator and aspirin have been convincingly demonstrated to be efficacious in human
clinical trials of treatments for acute ischaemic
stroke (5–7).
The systematic evaluation of all the available
and appropriate animal-based evidence, as well as
the outcomes of any other relevant preclinical
studies or evaluations, would provide a more realistic assessment of the likely benefits, or shortcomings, of various putative pharmaceuticals, and
would significantly decrease the number of such
compounds that progress to fruitless clinical trials.
It is partly because of this kind of reason that
the MRC requires researchers who are planning
human-based trials to reference systematic
reviews of related previous work before proceeding
(1). To facilitate the detection of toxicity, and to
provide insights into the factors which affect efficacy, such reviews should also include all relevant
animal research (8).
The need for a similar review process prior to
the performance of animal studies is aptly demonstrated by the disturbing number of cases in which
clinical trials have proceeded concurrently with, or
prior to, animal studies, or have continued despite
equivocal evidence of efficacy in animals (2). Such
cases clearly demonstrate that a significant number of animal researchers — and even some
human-based researchers — do not conduct adequate reviews of existing evidence, before commencing further studies.
It is clear that a comprehensive and rigorous
assessment of the available evidence should be a
more strict requirement, before further studies are
permitted to commence. Where neither sufficient
primary studies, nor systematic reviews of such
studies, exist, for the purposes of citation within a
licence application, researchers should be required
to demonstrate evidence that this is the case, and
also, that the available literature and evidence
have been adequately reviewed. In doing so, they
should also be able to demonstrate the need for
their proposed study, and should be able to appropriately position their experimental hypotheses
within the established body of knowledge.
Simon Festing also points out that certain information relevant to such a review may not yet have
achieved publication, for example, where results
are very recent, and that the rigorous inclusion criteria required of systematic reviews may prevent
the inclusion of such information in the results.
There is no reason, however, why such additional,
relevant information, cannot be included in the
discussion section of a systematic review, where
such material is of obvious relevance and importance.

712

Comment

Conclusions
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whether or not by the inclusion of published systematic reviews, before invasive animal studies
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Such a review should clearly demonstrate the
need and scientific appropriateness of the proposed study, within the context of existing knowledge, the validity of its design, and — importantly
— that the benefits are reasonably likely to exceed
the animal welfare, bioethical and financial costs.
Such studies should never be permitted solely on
the basis of less probable, speculative or intangible
human benefits, or the mere satisfaction of scientific curiosity.
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